Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Overview of important cervical cancer screening process values in European Union (EU) countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness.
van Ballegooijen M, van den Akker-van Marle E, Patnick J, Lynge E, Arbyn M, Anttila A, Ronco G, Dik J, Habbema F. van Ballegooijen M, et al. Among authors: van den akker van marle e. Eur J Cancer. 2000 Nov;36(17):2177-88. doi: 10.1016/s0959-8049(00)00330-0. Eur J Cancer. 2000. PMID: 11072201
Process performance of cervical screening programmes in Europe.
Ronco G, van Ballegooijen M, Becker N, Chil A, Fender M, Giubilato P, Kurtinaitis J, Lancucki L, Lynge E, Morais A, O'Reilly M, Sparen P, Suteu O, Rebolj M, Veerus P, Zakelj MP, Anttila A. Ronco G, et al. Among authors: van ballegooijen m. Eur J Cancer. 2009 Oct;45(15):2659-70. doi: 10.1016/j.ejca.2009.07.022. Epub 2009 Aug 25. Eur J Cancer. 2009. PMID: 19713100
Cervical cancer screening in the Netherlands.
van Ballegooijen M, Hermens R. van Ballegooijen M, et al. Eur J Cancer. 2000 Nov;36(17):2244-6. doi: 10.1016/s0959-8049(00)00317-8. Eur J Cancer. 2000. PMID: 11072213
Liquid-based cervical cytology using ThinPrep technology: weighing the pros and cons in a cost-effectiveness analysis.
de Bekker-Grob EW, de Kok IM, Bulten J, van Rosmalen J, Vedder JE, Arbyn M, Klinkhamer PJ, Siebers AG, van Ballegooijen M. de Bekker-Grob EW, et al. Among authors: van rosmalen j, van ballegooijen m. Cancer Causes Control. 2012 Aug;23(8):1323-31. doi: 10.1007/s10552-012-0011-1. Epub 2012 Jun 17. Cancer Causes Control. 2012. PMID: 22706692 Clinical Trial.
192 results